LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...

Q4 2025 Management View Jacob Leach, President, CEO & Director, marked his first call as CEO by outlining three strategic priorities: "We will be the premier glucose sensing solution for all," ...

DexCom, Inc. DXCM announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Dexcom said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United ...